GoodRx Holdings (GDRX) Depreciation & Amortization (CF) (2019 - 2026)

GoodRx Holdings has disclosed Depreciation & Amortization (CF) across 8 years of filings, most recently posting $21.8 million for Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $21.8 million, up 4.21% year-over-year; the trailing twelve-month figure through Mar 2026 was $86.1 million (up 15.56% YoY), and the FY2025 annual result was $85.2 million, up 22.55% from the prior year.
• Depreciation & Amortization (CF) came in at $21.8 million for Q1 2026 at GoodRx Holdings, down from $23.1 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $43.6 million in Q4 2023 to a low of $11.4 million in Q1 2022.
• The 5-year median for Depreciation & Amortization (CF) is $17.5 million (2024), against an average of $19.9 million.
• Across the five-year window, Depreciation & Amortization (CF) soared 180.74% in 2023 and plunged 56.21% in 2024, its largest moves.
• GoodRx Holdings' Depreciation & Amortization (CF) stood at $15.5 million in 2022, then jumped by 180.74% to $43.6 million in 2023, then slumped by 56.21% to $19.1 million in 2024, then rose by 21.21% to $23.1 million in 2025, then slipped by 5.85% to $21.8 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $21.8 million (Q1 2026), $23.1 million (Q4 2025), and $21.4 million (Q3 2025), per Business Quant data.